Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A clear, clinician-focused summary of the 2025 VA/DoD guideline update: new screening thresholds, streamlined treatment pathways, integration of pharmacotherapy (including GLP‑1 receptor agonists), endoscopic and surgical options, and veter
A 2026 study identifies a biologically distinct obesity subphenotype marked by fast gastric emptying, low GLP-1 synthesis, and substantially greater 6-month weight loss with tirzepatide.
Recent studies demonstrate that combining the beta-cell-targeted conjugate GLP1-E2 with low-dose anti-CD3 therapy significantly delays type 1 diabetes onset by simultaneously reducing immune infiltration and mitigating beta-cell cellular st
The World Health Organization (WHO) has released its landmark 2026 guidelines on GLP-1 therapies for obesity, reclassifying the condition as a chronic, relapsing disease requiring long-term pharmacological and behavioral management while em
This review synthesizes recent breakthroughs in obesity, type 2 diabetes, and lipidology, focusing on oral orforglipron, zodasiran for HoFH, and adolescent metabolic risk factors.
A randomized trial demonstrates that Dibifree, a novel dietary phytomix, improves HbA1c and adiposity in T2D patients by enhancing GLP-1 activity and modulating immune responses.
The ADA 2024 Standards update care pathways for diabetes with stronger guidance on obesity pharmacotherapy (GLP‑1/GIP agents), earlier use of SGLT2/GLP‑1 for cardiorenal benefit, and expanded technology recommendations.
A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatm
This trial evaluates dapagliflozin’s impact on key hormones and ketogenesis in type 1 diabetes, demonstrating increased ketone bodies without altering GLP-1, glucagon, or somatostatin secretion, highlighting risks and benefits for adj
A fermentable carbohydrate-enriched diet combined with metformin improves postprandial glycaemia, enhances GLP-1 secretion, and positively alters gut microbiota in prediabetic individuals, offering a personalized nutrition-pharmacology stra
A clinician-friendly summary of the American Diabetes Association’s 2024 Standards: who to screen, modern use of GLP‑1/GIP agents and SGLT2 inhibitors, continuous glucose monitoring, weight-management drugs, and implications for practice.
A practical, clinician-friendly summary of the American Diabetes Association’s 2024 Standards of Care, highlighting new recommendations on GLP-1/GIP therapy, SGLT2 inhibitors, continuous glucose monitoring, and individualized care.
The ADA’s 2024 Standards refocus diabetes care around cardiorenal protection, expanded use of GLP‑1 and SGLT2 therapies, wider adoption of glucose‑sensing technology, and integrated obesity management.
Combining metformin with a moderate FODMAP diet improves postprandial glucose control, enhances GLP-1 secretion, increases butyrate-producing gut bacteria, and reduces inflammation without worsening gastrointestinal side effects in prediabe
GLP-1 receptor agonist use, especially liraglutide, is associated with a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) during the first year, particularly in patients without diabetes or obesity.
Semaglutide drugs like Ozempic and Wegovy are transforming obesity treatment, but questions remain about long-term safety, access, and societal impact.
Exploring the science, benefits, risks, and realities behind Ozempic and other GLP-1 drugs in the fight against obesity.
New anti-obesity medications are transforming weight management, challenging old paradigms, and raising new questions about the future of dieting and health.